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Abstract
Background: Sex chromosome loss (SCL), including loss of an X chromosome (-X) in females and loss of the Y
chromosome (-Y) in males, resulting in a karyotype of 45,X, rarely occurs in patients post an allogeneic hematopoietic
stem cell transplant (alloHSCT). However, origin of this abnormal clone and its clinical significance remains unknown.
Results: We present 12 cases with SCL who underwent alloHSCT; 9 patients (4 men and 5 women with a median age
of 56 years) developed isolated SCL after alloHSCT (Group I), and 3 patients (all women with a median age of 58 years)
had a SCL before undergoing alloHSCT after which SCL disappeared (Group II). The primary neoplasms included
chronic lymphocytic leukemia (n = 5), acute myeloid leukemia (n = 5), chronic myelogenous leukemia with nodal
marginal zone lymphoma (n = 1) and Hodgkin lymphoma (n = 1). According to the donor/recipient relationship, their
alloHSCT can be divided into sex-matched, HLA-matched, unrelated donors (n = 2); sex-mismatched, HLA-matched,
unrelated donors (n = 4); sex-mismatched, HLA-matched, related donors (2 HLA-identical and 2 HLA-haploidentical
cases) and sex-matched, HLA-matched, related donors (2 HLA-haploidentical cases). In Group I, isolated SCL was
first detected with a median interval of 3 months (range 1 to 42 months) after the alloHSCT. By the end of clinical
follow-up in patients in Group I, 7 patients expired with a median overall survival of 45 months (range 3 to 108 months)
after alloHSCT and 33 months (range 0 to 66 months) after SCL detection. In Group II, 1 patient expired with a survival
time of 54 months after the alloHSCT. Detection of SCL after alloHSCT can be transient, intermittent or persistent.
Conclusions: Interpretation of SCL is challenging in the context of alloHSCT. Chimerism testing is useful in determining
the origin of SCL. In the case of SCL with donor/recipient chimerism, deduction of the SCL origin by all means and use
of “–?X” or “–?Y” in the ISCN nomenclature are recommended. Clinical follow-up with closely monitoring the SCL by both
cytogenetic and molecular analyses is needed.
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Background
Sex chromosome loss (SCL), defined as loss of an X
chromosome in a female (minus X or –X) or loss of the
Y chromosome (minus Y or -Y) in a male, is commonly
observed in healthy individuals with advancing age. It is
considered to be an age-related nondisjunction
phenomenon. However, in patients with various
hematologic malignancies, detection of –X or –Y has
been interpreted, at least in some cases, as evidence of
an abnormal clonal karyotype, although the clinical im-
pact of SCL as a biomarker for a hematologic malig-
nancy is elusive [1–11].
Human leukocyte antigen (HLA) matched hematopoietic
stem cell transplant (HSCT) is considered a highly effective
treatment or even a permanent cure for several
hematologic malignancies. This type of therapy is widely
applied in the clinical practice, e.g., there have been over 1
million HSCTs performed between 2006 and 2014 world-
wide [12–14], and 19,220 HSCTs (10,872 autologous
(autoHSCTs) and 8348 allogeneic (alloHSCTs)) in the
United States in 2013 alone [15]. Due to a possible co-
existence of cells originated from both donor and recipient,
interpreting the finding of a SCL after an alloHSCT can be
very challenging, depending on multiple factors, such as
age of donor and recipient, type of alloHSCT (sex-matched
vs. sex-mismatched; related vs. unrelated donor; identical
vs. haploidentical), level of chimerism, technical limits of
methods used for detection of SCL and other factors.
Here we report 9 patients who developed isolated
SCL after an alloHSCT, and their donor types included
sex-matched, unrelated; sex-mismatched, unrelated;
sex-mismatched, related HLA-haploidentical and sex-
mismatched, related HLA-identical. We also report 3
additional patients who had SCL prior to alloHSCT
after which SCL disappeared which we consider as a
control group. We focus on the challenges of interpret-
ing SCL in these complicated clinical scenarios, along
with our recommendations for reporting and interpret-
ing the SCL findings.
Methods
Patients
We searched the Clinical Cytogenetics database in the
Department of Hematopathology at The University of
Texas MD Anderson Cancer Center for –X or –Y as the
sole chromosomal abnormality in patients with a history
of allogeneic SCT from November, 2000 through
December, 2015. Patients with any other chromosomal
abnormalities in addition to –X or -Y were excluded
from this study. Detailed clinical and laboratory informa-
tion were collected and reviewed following institutional
guidelines with informed consent in accord with the
Declaration of Helsinki.
Conventional chromosomal analysis
Conventional chromosomal analysis (karyotyping) was
performed on G-banded metaphase cells prepared from
unstimulated 24-h (24 h) and 48-h (48 h) bone marrow
cultures as reported previously [11]. Routinely, 20 meta-
phases were analyzed per case, but less or more than 20
metaphases were analyzed in some cases, due to either
an inadequate metaphases available for a complete ana-
lysis or a request by a Cytogeneticist for more intensive
analysis. Clonal SCL was defined as –X or –Y detected
in 3 or more cells of the same analysis, and only patients
with clonal SCL were included in this study. All results
were reported according to the International System for
Human Cytogenetic Nomenclature 2013 (ISCN2013)
guidelines [16].
Fluorescence in situ hybridization (FISH) analysis
The Vysis XY dual color probe set, SpectrumOrange
Probe targeting Xp11.1-q11.1 alpha satellite DNA,
DXZ1 and SpectrumGreen Probe targeting Yq12 satellite
III DNA, DYZ1 (Abbott Molecular, Des Plaines, IL) was
used for FISH analysis following established procedures
in the Clinical Cytogenetics Laboratory [11]. A total of
400 interphases was counted in each case by two
readers.
PCR-based microsatellite polymorphism (chimerism)
analysis
PCR-based microsatellite polymorphism analysis was
performed on specimens collected from donors and re-
cipients. Briefly, genomic DNA was extracted from bone
marrow aspirate specimens and subjected to one
multiplex-PCR amplification of 8 informative short tan-
dem repeat (STR) markers (D6S264, D3S1282, D18S62,
D3S1300, DM1, AR, D11S987 and D9S171). The
fluorescence-labeled PCR products were subsequently
fractionated on an ABI 3100 Genetic Analyzer and ana-
lyzed using GeneScan 2.1 software (Thermo Fisher
Scientific, Waltham, MA). Patients were followed after
alloHSCT at various intervals according to different pro-
tocols at MD Anderson over the years. The post-
transplant STR information of recipient was compared
with the pre-transplant STR information of both donor
and recipient to evaluate for the level of chimerism.
Results
Patients and allogeneic hematopoietic stem cell
transplants (alloHSCTs)
The study is composed of two groups of cases. Patients
in Group I (cases 1 to 9) had acquired isolated clonal
SCL after alloHSCT. Patients in Group II (cases 10 to
12) had isolated SCL before alloHSCT (Table 1). The 9
patients in Group I were 4 men and 5 women with a
median age of 56 years (range 26-69 years) when isolated
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SCL was detected after alloHSCT. The primary diseases
of these patients included chronic lymphocytic leukemia
(CLL) in 4 cases; acute myeloid leukemia (AML) in 3
cases; chronic myelogenous leukemia (CML) with nodal
marginal zone lymphoma in 1 case; and Hodgkin lymph-
oma in 1 case. In this group, 2 patients received
alloHSCT from sex-matched, HLA-matched, unrelated
donors (cases 1 and 8) and 7 patients (cases 2 to 7
and 9) from sex-mismatched donors; 4 received alloHSCT
from unrelated donors (cases 2 and 5 to 7), 3 from related
donors (2 from HLA-identical sister, cases 3 and 4; and 1
from HLA-haploidentical father, case 9). Four patients
(cases 1, 2, 5 and 6) received alloHSCT from anonymous
donors through the Matched Unrelated Donor Transplant
(MUD) program and ages of these donors are not avail-
able. In Group II, 3 female patients had a median age of
58 years (range 19-66 years) when isolated SCL was ini-
tially detected prior to alloHSCT. Their SCL disappeared
after the alloHSCT. In this group, all 3 patients received
alloHSCT from HLA-haploidentical related donors
(2 sex-matched, 1 sex-mismatched). In this study, all
patients received a BM alloHSCT except one (case 7) who
received 2 separate PB alloHSCTs from the same donor.
Her SCL had occurred after the second PB alloHSCT.
The clinical features and donor information for each
patient listed in Table 1.
Cytogenetic analysis
In Group I, all patients had a normal diploid karyotype
through preparative therapy (e.g., chemotherapy of vari-
ous regimens) prior to alloHSCT. An isolated SCL was
first detected with a mean interval of 12 months (range,
1 to 42 months) after the alloHSCT. The clone size of
SCL was 15 to 25 % or 3 to 5 metaphases per 20-
metaphase analysis in all 9 patients. One patient (case 5)
died within one month after the detection of SCL,
whereas the other patients have been followed-up for a
mean interval of 33 months (range 5 to 66 months).
During follow-up all 8 patients had at least 2 more con-
ventional cytogenetic analyses, and/or FISH analysis.
The SCL was detected consistently in 3 patients (cases 1,
3 and 4), intermittent in 3 patients (cases 6, 8 and 9)
and was not detected in subsequent specimens in 2 pa-
tients (cases 2 and 7) (data not included). The most re-
cent conventional cytogenetic analysis in case 8 detected
a –X in one metaphase; although not a clonal abnormal-
ity, it is still included in the nomenclature for the pur-
pose of documentation as well as reference for future
analyses.
In Group II, initial SCL detection was 2, 1 and
12 months prior to alloHSCT in cases 10, 11 and 12, re-
spectively. In addition to SCL, cases 10 and 11 had both
inv(9)(p12q13) which is considered as chromosomal
polymorphism found in the general population without
known clinical significance, but can be used as marker
to distinguish recipient and donor cells. Case 12 had a
t(8;21)(q22;q22). After alloHSCT, the SCL disappeared
in all 3 cases during a follow-up interval of 12 to
54 months. One patient (case 11) developed disease re-
lapse and died whereas two patients (cases 10 and 12)
remained as a complete remission.
Microsatellite polymorphism (chimerism) analysis
In Group I, the bone marrow aspirate specimen showed
100 % donor cells at time of first detection of SCL in 6
patients (cases 1 and 5-9). Therefore, their SCL was con-
sidered to originate from donor cells. This status of
100 % donor cells remained unchanged in 4 patients
(cases 1, 6, 8 and 9) during a follow-up of 12, 5, 11 and
38 months, respectively, but converted into a chimerism
with a mixture of donor and recipient cells at the end of
follow-up of 66 months in case 7 (based on the latest
cytogenetic analysis). One patient (case 5) died shortly
after the detection of SCL. Bone marrow aspirate speci-
mens collected from 3 patients (cases 2, 3, and 4)
showed chimerism with a mixture of donor and recipi-
ent cells when SCL was initially detected. During a
follow-up of 33 to 58 months, the chimerism persisted
in two patients (cases 2 and 3), but converted into 100 %
recipient cells in case 4 (based on both conventional
cytogenetic analysis and chimerism tests). In group II, a
status of 100 % donor cells after alloHSCT remained un-
changed in two patients (cases 10 and 12) during a
follow-up of 12 and 13 months; 100 % donor cells was
reached, but shortly thereafter converted to chimerism
in one patient (case 11).
Follow-up and outcome
At last clinical follow-up, 7 patients had died (cases 1 to 7)
and 2 patients remain alive in complete remission (cases 8
and 9) in Group I. For the 7 deceased patients in this group,
their mean survival time were 32 months (range 3 to
108 months) after the alloHSCT and 24 months (range 0 to
66 months) after detection of SCL. Four patients (cases 1,
5-7) had developed graft-versus-host disease (GVHD), 5 pa-
tients (cases 1 to 4-7) had a relapse of primary disease, and
one patient (case 5) had persistent primary disease (CLL)
after alloHSCT (Table 1). In Group II, 1 patient died (case
11) and 2 patients were alive with complete remission
(cases 10 and 12). Two patients had a GVHD (cases 10 and
11) and 1 had a relapse of primary disease (case 11).
Discussion
When sex chromosome loss (SCL) after alloHSCT is en-
countered, one of the biggest challenges is to determine
the origin of the SCL. Is the SCL originally from the
donor or the recipient cells? Is the SCL actually a -X or
a -Y in a sex-mismatched alloHSCT case?
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Determination of the origin of cells with chromosomal
aberration(s) is very important in a predicted negative
event, such as disease relapse, graft rejection and GVHD,
or donor cell hematologic malignancies [17, 18] and is
helpful for determining appropriate intervention or ther-
apy [19]. However, for isolated SCL after alloHSCT, nei-
ther karyotyping nor FISH analyses are useful to
determine the origin of SCL. A positive SCL result de-
tected by one of these two methods is usually described
as “–X or –Y”. In contrast, microsatellite polymorphism
analysis, by detecting short tandem repeat (STR)
markers in the engraftment (chimerism test), is very use-
ful to address the question of origin. In Group I of this
study, the origin of SCL was deduced by the chimerism
testing results indicating either 100 % donor cell origin
or 100 % recipient origin in 6 patients (cases 1, 5-9) at
the time SCL was detected initially and in 5 patients
(cases 1, 4, 6, 8 and 9) at the last CG analysis and chime-
rism test. The “-X” or “-Y” in the ISCN description in
Table 1 was concluded from a combination of the CG
analysis and chimerism test results. It must be noted
that both sensitivity and specificity of chimerism testing
can be impacted by multiple factors, for example, rela-
tionship of donor and recipient (e.g., monozygotic
twins), number and selection of STR markers, and speci-
men quality as well as other factors [20, 21].
For an ideally successful alloHSCT, the recipient’s
hematopoietic and lymphoid cells in bone marrow are
replaced by cells derived from the donor HSCs. How-
ever, a status of recipient-donor chimerism (henceforth
referred to as chimerism), in other words co-existence of
recipient and donor cells, can be possible in certain
cases. Patients without a pre-alloHSCT ablative prepar-
ation and patients having a post-alloHSCT relapse are
especially susceptible to developing chimerism in their
bone marrow [19]. In this study, 3 patients (cases 2-4)
exhibited chimerism at the time SCL was initially de-
tected and 4 patients (cases 2, 3, 7 and 11) at the last
post-alloHSCT follow-up tests (CG analysis and/or chi-
merism test). The origin of SCL in these cases (except
case 11) remains unknown. For these cases, writing up
an appropriate nomenclature can be challenging for a
Cytogeneticist. The previous descriptions of “–X or –Y”
is not able to set the clonal SCL in an appropriate spot
of the ISCN description where a “//” is used to separate
recipient karyotype(s) from donor karyotype(s). There-
fore, we recommend the following rules: 1. use “–?X” or
“–?Y” instead of “–X or –Y” to describe the SCL. In this
way, the SCL can be classified as part of recipient cells
(e.g., cases 2-4) or donor cells (e.g., case 7) in sex-
mismatched alloHSCT cases; 2. Deduce the most likely
origin of SCL in cases with a chimerism by correlating
previous SCL results, other additional chromosomal ab-
erration(s) and chimerism test results. For example, SCL
plus a polymorphism (such as inv(9) in cases 10 and 11)
or a recurrent chromosome aberration which had pre-
sented in the recipient previously, usually indicates that
the origin of SCL is most likely recipient cells. In this
study, the origin of SCL was sustained in all cases with a
status of 100 % donor cells (cases 1, 6 and 9) and a con-
verted status of 100 % recipient cells (case 4) during
follow-up. A conversion of SCL origin from recipient to
donor cells or vice versa was not been observed in this
study. Therefore, a deduction of SCL origin with a “–?X”
or a “–?Y” may help for better monitoring cases with
chimerism.
The causes of SCL in patients with hematologic malig-
nancies can be multifactorial. As we reported recently
[11], an age-related “physical event”; selective advantage
of SCL clone; hematologic malignancies themselves and
certain interventions, such as chemotherapy, all can
cause SCL. In this study, several patients and donors
were ≥ 60 years of age when the alloHSCT was per-
formed and therefore an age-related nondisjunction
phenomenon may play a role. In addition, all patients in
this study were treated with and subsequently weaned
off immunosuppressive agents to prevent GVHD; 6 pa-
tients had GVHD of various severity. As hypothesized
by other research groups [22, 23], immunosuppressive
intervention and GVHD could cause SCL in these pa-
tients as well.
Five patients from Group I and 1 patient from Group II
had a relapse of disease; 7 patients from Group I and 1 pa-
tient from Group II died during follow-up. Due to the het-
erogeneity of disease and clinical course in each patient as
well as the limited number of cases available for stratifica-
tion and further analyses in this study, it is difficult to cor-
relate SCL with outcomes. Therefore, interpreting the
clinical significance of SCL after alloHSCT is another chal-
lenge for a Cytogeneticist. It has been reported previously
that a clonal -Y resulting in a loss of minor histocompatibil-
ity antigens on the Y chromosome (HY) is associated with
loss of graft-versus-leukemia (GVL) effect and hematologic
relapse in male patients with myeloid or lymphoid leukemia
after a sex-mismatched alloHSCT [23]; even a mosaic loss
of chromosome Y in peripheral blood can be associated
with shorter survival and higher risk of cancer as was
shown in a huge population-based study [24]. Loss of X
chromosome (-X) may be disease-associated in patients
with myeloid malignancies [11]. Therefore, we recommend
that SCL after alloHSCT be considered as a clonal abnor-
mality with potential clinical significance. Instead of imme-
diate intervention, close monitoring of the SCL by both
cytogenetic and molecular analyses seems warranted.
Conclusions
In summary, determining the origin of an acquired iso-
lated SCL after alloHSCT can be challenging to
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Cytogeneticists. The clinical impact of isolated SCL can
be difficult; for some patients, careful follow up seems
indicated. Lastly, integrating SCL into an appropriate
ISCN nomenclature is also challenging and we suggest a
minor change in terminology to accommodate this issue.
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